No Matches Found
No Matches Found
No Matches Found
Precigen, Inc.
Precigen Stock Opens Weak with 11.75% Gap Down Amid Market Concerns
Precigen, Inc. has opened with a notable loss, continuing a trend of significant declines over the past month. The company's market capitalization is around USD 1.265 billion, with a high return on equity but a negative price-to-book ratio. Technical indicators present mixed signals regarding its performance outlook.
Precigen, Inc. Hits Day Low of $4.21 Amid Price Pressure
Precigen, Inc. faced a notable stock decline today, reaching an intraday low. Despite recent gains and impressive annual returns, the company grapples with significant financial challenges, including operating losses, declining net sales, and a concerning debt situation, indicating a complex landscape in the biotechnology sector.
Precigen, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance
Precigen, Inc. has reported mixed financial results for the quarter ending June 2025, highlighting both challenges and strengths. While the company experienced significant reductions in raw material costs and efficient receivables management, it also faced low return on capital and high debt levels. Market performance has been resilient, but long-term outlook remains uncertain.
Precigen, Inc. Soars 26.94% to Hit Intraday High of $5.00
Precigen, Inc. has seen notable stock activity, achieving significant gains both recently and year-to-date. Despite impressive short-term performance, the company faces long-term challenges, including operating losses and a high debt-equity ratio, raising concerns about its future growth prospects in the biotechnology sector.
Precigen, Inc. Hits Day High with 25.65% Surge in Stock Price
Precigen, Inc. has seen notable stock activity, with a significant increase today and impressive gains over the past week and month. Despite its strong year-to-date performance, the company faces challenges such as operating losses and declining net sales, raising concerns about its long-term financial stability.
Precigen, Inc. Hits Day High with 10.31% Surge in Strong Intraday Performance
Precigen, Inc. has seen a notable increase in stock performance, achieving a significant rise today. Over the past year, the company has outperformed the S&P 500, with substantial year-to-date gains. However, it faces challenges such as operating losses, declining net sales, and a high debt-to-equity ratio.
Precigen, Inc. Opens with a 5.13% Gain Amid Ongoing Challenges
Precigen, Inc. experienced a notable gain today, contrasting with broader market declines. Despite this uptick, the company has faced significant challenges, including declining net sales and operating losses over the past five years, raising concerns about its long-term financial stability and ability to service debt.
Precigen, Inc. Hits Day Low of $3.47 Amid Price Pressure
Precigen, Inc. saw a notable decline in its stock price, contrasting with the broader market's performance. Despite a substantial year-over-year growth, the company faces challenges, including significant operating losses, a high debt-equity ratio, and declining net sales, raising concerns about its financial stability.
Is Precigen, Inc. technically bullish or bearish?
As of July 7, 2025, Precigen, Inc. shows a bullish technical trend despite some short-term weakness indicated by the weekly RSI, having outperformed the S&P 500 significantly with a year-to-date return of 239.29% compared to 12.22%.
Precigen, Inc. Hits Day High with Strong 8.36% Intraday Surge
Precigen, Inc. has seen notable stock performance, with significant gains over various timeframes, including a year-to-date increase of 247.32%. Despite this, the company faces challenges such as operating losses and declining net sales, indicating a complex market position amid its recent volatility.
Is Precigen, Inc. technically bullish or bearish?
As of May 22, 2025, the trend has shifted to mildly bullish due to daily moving averages, although caution is advised from weekly indicators showing mild bearishness.
Who are in the management team of Precigen, Inc.?
As of March 2022, the management team of Precigen, Inc. includes Executive Chairman Randal Kirk, Lead Independent Director Robert Shapiro, and Independent Directors Cesar Alvarez, Steven Frank, Vinita Gupta, and Fred Hassan. This team provides governance and strategic direction for the company.
What does Precigen, Inc. do?
Precigen, Inc. is a biotechnology company focused on developing biologically-based products using synthetic biology, with a market cap of approximately $427.89 million. As of March 2025, it reported net sales of $1 million and a net loss of $54 million.
How big is Precigen, Inc.?
As of Jun 18, Precigen, Inc. has a market capitalization of 427.89 million, with net sales of 4.20 million and a net profit of -156.65 million over the latest four quarters. Shareholder's funds are 66.73 million, and total assets amount to 146.54 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
